Evidence map›Paper›PMID 40577677›Full record

ArticleNeurology2025

An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders.

Leland Barnard, Hugo Botha, Nick Corriveau-Lecavalier, Jonathan Graff-Radford, Ellen Dicks, Venkatsampath Gogineni, Gemeng Zhang, Brian J Burkett, Derek R Johnson, Sean J Huls and 23 more

Abstract read
In one paragraph

Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Real-world comparison of brain [EClinicalMedicine · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Beyond black-box AI: Interpretable hybrid systems for dementia care.Alzheimer's & dementia (Amsterdam, Netherlands)
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Leland BarnardNeurology, Mayo Clinic, Rochester, MN.
Hugo BothaNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4390-685X
Nick Corriveau-LecavalierPsychiatry and Psychology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6561-9870
Jonathan Graff-RadfordNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2770-0691
Ellen DicksNeurology, Mayo Clinic, Rochester, MN.
Venkatsampath GogineniNeurology, Mayo Clinic, Rochester, MN.
Gemeng ZhangNeurology, Mayo Clinic, Rochester, MN.
Brian J BurkettRadiology, Mayo Clinic, Rochester, MN.
Derek R JohnsonRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4217-5517
Sean J HulsRadiology, Mayo Clinic, Rochester, MN.
Aditya KhuranaRadiology, Mayo Clinic, Rochester, MN.
John L StrickerInformation Technology, Mayo Clinic, Rochester, MN.
Hoon-Ki Paul MinRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-1084-2469
Matthew L SenjemInformation Technology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-9308-9275
Winnie Z FanQuantitative Health Science, Mayo Clinic, Rochester, MN.
Heather WisteQuantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0009-0002-8833-2693
Mary M MachuldaPsychiatry and Psychology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4834-5967
Melissa E MurrayNeuroscience, Mayo Clinic, Jacksonville, FL; and.ORCID 0000-0001-7379-2545
Dennis W DicksonNeuroscience, Mayo Clinic, Jacksonville, FL; and.ORCID 0000-0001-7189-7917
Aivi T NguyenLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-1809-9451
R Ross ReichardLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-0842-2462
Jeffrey L GunterRadiology, Mayo Clinic, Rochester, MN.
Christopher G SchwarzRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-1466-8357
Kejal KantarciRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-8001-2081
Jennifer L WhitwellRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6914-1563
Keith Anthony JosephsNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2930-8634
David S KnopmanNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6544-066X
Bradley F BoeveNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4153-8187
Ronald C PetersenNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-8178-6601
Clifford R JackRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-7916-622X
Val J LoweRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-5612-1667
David T JonesNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4807-9833
Alzheimer's Disease Neuroimaging Initiative

Funding

Longitudinal multi-modality imaging in progressive apraxia of speech (Diversity Supplement)R01DC012519 · NIDCD · MAYO CLINIC ROCHESTER · PI Jennifer Louise Whitwell · 2013 to 2026
$7.2M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal studyR01AG050603 · NIA · MAYO CLINIC ROCHESTER · PI WHITWELL, JENNIFER LOUISE · 2016 to 2025
$5.9M
Longitudinal Multi-modal Imaging in Progressive Supranuclear Palsy SyndromesR01NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2015 to 2024
$5.6M
Longitudinal multi-modal imaging in progressive supranuclear palsy syndromesR37NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Jennifer Louise Whitwell · 2026 to 2026
$3.7M
NIA NIH HHS R01 AG050603NIA NIH HHS R37 AG011378NIDCD NIH HHS R01 DC012519NINDS NIH HHS R01 NS089757NINDS NIH HHS R37 NS089757
6 · The paper itself

Abstract

BACKGROUND AND

objectivesDistinguishing neurodegenerative diseases is a challenging task requiring neurologic expertise. Clinical decision support systems (CDSSs) powered by machine learning (ML) and artificial intelligence can assist with complex diagnostic tasks by augmenting user capabilities, but workflow integration poses many challenges. We propose that a modeling framework based on fluorodeoxyglucose PET (FDG-PET) imaging can address these challenges and form the basis of an effective CDSS for neurodegenerative disease.

methodsThis retrospective study focused on FDG-PET images in a discovery cohort drawn from 3 research studies plus routine clinical patients. When selecting research study participants, the inclusion criterion was the availability of an FDG-PET image from within 2.5 years of diagnosis with 1 of 9 specific neurodegenerative syndromes or designation as unimpaired. Participants from disease groups were recruited from the clinical patient population while unimpaired participants came primarily from a population study. The discovery cohort was used to develop a clinical decision support framework we call StateViewer, which applies a neighbor matching algorithm to detect the presence of 9 different neurodegenerative phenotypes. The ML performance of this framework was evaluated in the discovery cohort by nested cross-validation and externally validated in the Alzheimer's Disease Neuroimaging Initiative. Potential for clinical integration was demonstrated in a radiologic reader study focused on differentiating posterior cortical atrophy from Lewy body dementia.

resultsThe discovery cohort contained 3,671 individuals with a mean age of 68 years and consisted of 49% reported female. Our model framework was able to detect the presence of 9 different neurodegenerative phenotypes with a sensitivity of 0.89 ± 0.03 and an area under the receiver operating characteristic curve of 0.93 ± 0.02. In the radiologic reader study, readers using our model were found to have 3.3 ± 1.1 times greater odds of making a correct diagnosis than readers using a current standard-of-care workflow. DISCUSSION: Our proposed framework provides strong classification performance with high interpretability, and it addresses many of the challenges that face clinical integration of ML-based decision support tools. One limitation of this study is a uniform discovery cohort that is not representative of other patient populations in some regards.

Indexed as

Alzheimer DiseaseClinical Decision-MakingDecision Support Systems, ClinicalMachine LearningNeurodegenerative DiseasesPositron-Emission TomographyAgedAged, 80 and overCohort StudiesFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedRetrospective StudiesFluorodeoxyglucose F18

Identifiers

PMID40577677
PMCPMC12207676

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.